Sadeghi H Mehrdad, Stone Gregg W, Grines Cindy L, Mehran Roxana, Dixon Simon R, Lansky Alexandra J, Fahy Martin, Cox David A, Garcia Eulogio, Tcheng James E, Griffin John J, Stuckey Thomas D, Turco Mark, Carroll John D
William Beaumont Hospital, Royal Oak, Mich, USA.
Circulation. 2003 Dec 2;108(22):2769-75. doi: 10.1161/01.CIR.0000103623.63687.21. Epub 2003 Nov 24.
The prognostic importance of renal insufficiency (RI) in patients undergoing primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) has not been well characterized.
PCI was performed in 2082 AMI patients without shock presenting within 12 hours of symptom onset in a prospective, multicenter randomized trial. RI was defined as a calculated (Cockroft-Gault) creatinine clearance (CrCl) < or =60 mL/min. RI at baseline was present in 18% of patients. Compared with patients without RI, patients with RI were older and were more likely to be female; to have hypertension, peripheral vascular disease, or cerebrovascular disease; and to present in heart failure. Mortality was markedly increased in patients with versus without baseline RI both at 30 days (7.5% versus 0.8%, P<0.0001) and at 1 year (12.7% versus 2.4%, P<0.0001). Mortality rates increased incrementally for every 10-mL/min decrease in baseline CrCl. By multivariate analysis, reduced baseline CrCl was a powerful independent predictor of 30-day mortality (hazard ratio, 5.77; P<0.0001) and remained associated with reduced survival at 1 year (hazard ratio, 1.98; P=0.08). Hemorrhagic complications and transfusion requirements were also increased more than 2-fold in patients with RI, as were severe restenosis (diameter stenosis > or =70%; 20.6% versus 11.8%, P=0.024) and infarct artery reocclusion (14.7% versus 7.3%, P=0.02).
Baseline RI in patients with AMI undergoing primary PCI is associated with a markedly increased risk of mortality, as well as bleeding and restenosis. Novel approaches are needed to improve the otherwise poor prognosis of patients with RI and AMI.
对于因急性心肌梗死(AMI)接受直接经皮冠状动脉介入治疗(PCI)的患者,肾功能不全(RI)的预后重要性尚未得到充分描述。
在一项前瞻性多中心随机试验中,对2082例症状发作12小时内无休克的AMI患者进行了PCI。RI定义为计算得出的(Cockcroft-Gault)肌酐清除率(CrCl)≤60 mL/分钟。18%的患者基线时存在RI。与无RI的患者相比,有RI的患者年龄更大,更可能为女性;患有高血压、外周血管疾病或脑血管疾病;且出现心力衰竭。有基线RI与无基线RI的患者相比,30天时死亡率显著增加(7.5%对0.8%,P<0.0001),1年时死亡率也显著增加(12.7%对2.4%,P<0.0001)。基线CrCl每降低10 mL/分钟,死亡率逐步增加。多因素分析显示,基线CrCl降低是30天死亡率的有力独立预测因素(风险比,5.77;P<0.0001),且与1年生存率降低相关(风险比,1.98;P=0.08)。RI患者的出血并发症和输血需求也增加了2倍多,严重再狭窄(直径狭窄≥70%;20.6%对11.8%,P=0.024)和梗死动脉再闭塞(14.7%对7.3%,P=0.02)也是如此。
接受直接PCI的AMI患者基线RI与死亡率、出血及再狭窄风险显著增加相关。需要新的方法来改善RI合并AMI患者原本不佳的预后。